Phase 4 N=421 Pain Increases After Shoulder Injection
Shoulder Pain
Primary: Incidence of a Flare Reaction — 44; 8; 149; 191 Person-visits
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Age-related Macular Degeneration · Central Retinal Vein Occlusion · Diabetic Macular Edema
Primary: Number of Participants Who Preferred Subconjunctival Anesthetic at the Third Follow-up Visit — 50 participants
Phase 4 N=31 Pain Outcomes Following Intralesional Corticosteroid Injections
Keloid · Alopecia Areata · Acne
Primary: Pain Outcome: Visual Analog Scale — 5.4; 2.7 Score on a scale
Phase 1 N=18 A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs
Healthy
Primary: The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema). — 0; 51; 0; 0 injections
N/A N=160 Success Rate of 4 Injection Protocols for Mandibular First Molars With Symptomatic Irreversible Pulpitis
Root Canal Infection
Primary: Number of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS) — 16; 37; 29; 26 Participants
N/A N=90 The Role of Proper Insulin Injection Technique in the Treatment of Diabetes Mellitus
Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Lipohypertrophy
Primary: Change in Glycemic Control — 8.99; 8.20 % of glycated hemoglobin
N/A N=64 Corticosteroid Injection for Common Upper Extremity Problems
Lateral Elbow Pain
Primary: Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire — 18; 13 units on a scale
N/A N=120 Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics
Bacterial Resistance
Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants
N/A N=60 Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection
Trigger Finger
Primary: Difference in Visual-analog Score (VAS) for Anticipated Pain Prior to Injection and Actual Pain After Injection — 1.6; 2.8 units on a scale
Phase 4 N=69 Long Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone
Trigger Finger Disorder
Primary: Number of Participants With no Symptoms of Trigger Finger — 28; 9 Participants
N/A N=86 Safety and Effectiveness Clinical Evaluation of Injectable Medical Devices Viscol
Aesthetic Dermatology
Primary: Performance at 1 Month Investigator Overall VISCOL Range — 77 Participants — p=<0.0001
N/A N=20 Dispersal Pattern for Spine Injections (Gadolinium Contrast)
Cervical Radiculopathy
Primary: Injection Dispersal Patterns Measured (in cm) in the Superoinferior Directions on Post-injection MRI With a Calibrated Internal Measurement Software. — 14.73 cm
N/A N=162 Comparison of Intravascular Uptake and Pain Perception During Epidural Injection Using 22 Gauge vs 25 Gauge Needle
Pain · Needle Injury
Primary: Intravascular Uptake — 5.9; 7.1 percentage of total number of needle
N/A N=73 Effect of Sedation on Diagnostic Injections
Sacroiliac Joint Pain · Sympathetically Maintained Pain
Primary: Pain Score — 2.2; 3.4 units on a scale
N/A N=152 Complications Associated With Central Venous Access in the NSICU: PICC vs CVC
PICC · Central Venous Catheter · Central Line
Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271
Phase 4 N=204 Intravenous Oliceridine and Opioid-related Complications
Major Surgery
Primary: Clinically Meaningful Respiratory Compromise Events — 45 Events
Phase 1 N=82 Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations
Diabetes · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Injection Pain (VAS mm) — 20.0; 12.8; NA; NA mm
N/A N=133 Patterns and Prevalence of FDG Extravasation in PET/CT Scans
Intravenous Infiltration
Primary: Number of Participants With Intraveneous Infiltration of FDG During Routine PET/CT Imaging by Visually Assessment of Interpreting Physicians — 17; 32 Participants
Phase 4 N=190 Effects of a Surgical Site Injection on Pain Scores and Narcotic Use After Orthopaedic Trauma Surgery
Pertrochanteric Fracture
Primary: Amount (mg) of Narcotics (Oral Morphine mg Equivalents) Used — 16; 10 morphine milligram equivalents (MME)
N/A N=212 Midlines and Thrombophlebitis
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants
Phase 1 N=41 Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis
Chronic Plantar Fasciitis
Primary: Visual Analog Scale Score - General Heel Tenderness — 46.7; 47.5 score on a scale
Phase 4 N=156 Preventing Propofol-associated Injection Pain
Pain
Primary: Verbal Pain Score — 3; 0; 0 Units on a scale — p=<0.0001
N/A N=120 Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection
Bursitis
Primary: Pain Intensity Measured on Visual Analog Scale and Percent Improvement
Phase 4 N=110 Trigger Finger Corticosteroid Injection With and Without Local Anesthetic
Trigger Finger
Primary: Pain Outcome: Visual Analog Scale — 3.5; 2 score on a scale
Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
Phase 4 N=108 Procedural Discomfort Related to Number of Intradetrusor Botox Injections
Overactive Bladder
Primary: Participant Discomfort Related to BTX-A Injection — 3.2; 3.6 score on a scale — p=0.21
N/A N=79 Use of BIP-Needles in Rheumatologic Injections
Intra-articular Injections
Primary: True Positive Detection of Synovial Fluid Marked in Case Report Form — 86 percentage of injected joints
Phase 2 N=64 Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)
Edematous Skin
Primary: Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 22 — 1.08; 1.10; 0.75; 0.50 score on a scale
N/A N=100 Assessment of Novel Intraocular Injection Guide
Retinal Disease
Primary: Visual Analogue Scale (VAS) — 14; 33 mm on the VAS
Phase 2 N=104 A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
Healthy Volunteers Diabetes Mellitus, Type 2 · Healthy Volunteers Overweight · Healthy Volunteers Obesity
Primary: Intensity of Injection Site Pain — 8.3; 5.7 Score on a scale — p=0.0395